SubsidieMeestersKRAS-AlphaTACs: a novel class of biotherapeutics to target KRAS
The project aims to develop and pre-clinically validate AlphaTACs for targeted degradation of KRAS proteins to advance cancer therapy and support a new spin-off company.
Projectdetails
Introduction
The RAS pathway is the most frequently activated signaling node in human cancer. Activating KRAS mutations are found in approximately one in seven human cancers.
KRAS Signaling
KRAS signaling is also activated in a significant subset of human cancers that lack KRAS mutations. Targeting KRAS has been a central goal during the past four decades, and the efforts have intensified over the past years, ignited by the approval of the KRAS-G12C inhibitors.
Targeted KRAS Degradation
A targeted KRAS degradation approach is an attractive solution for blocking KRAS activity. Within the Ub-RASDisease project, we explored the degradability of wild-type and mutant KRAS proteins.
AlphaTAC Technology
In parallel, my group initiated studies to combine the Alphabody technology with the targeted protein degradation approach by designing an AlphaTAC as a novel therapeutic modality.
Project Goals
The goal of this project is to generate and pre-clinically validate AlphaTACs targeting KRAS for degradation. This will strengthen the proof of concept on the AlphaTAC utility in targeted protein degradation and provide support for establishing a proprietary platform in view of the creation of a new spin-off company.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-8-2023 |
| Einddatum | 31-1-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- VIB VZWpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal AdenocarcinomaPROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity. | ERC COG | € 1.999.401 | 2023 | Details |
Unlocking a T cell-mediated Immune response in therapy-challenged TumorsUnlockIT aims to develop mechanism-based combination therapies for cancer by understanding tumor-immune interactions and enhancing T cell responses in therapy-challenged tumors. | ERC COG | € 2.000.000 | 2024 | Details |
Unraveling mechanisms of drug resistance: APOBEC3A as a genomic and post-transcriptional driver of treatment resistance in pancreatic cancerThe ADRIP study aims to investigate the role of APOBEC3A in driving drug resistance and intra-tumoral heterogeneity in pancreatic cancer, with potential therapeutic implications. | ERC STG | € 1.880.615 | 2025 | Details |
Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal Adenocarcinoma
PROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity.
Unlocking a T cell-mediated Immune response in therapy-challenged Tumors
UnlockIT aims to develop mechanism-based combination therapies for cancer by understanding tumor-immune interactions and enhancing T cell responses in therapy-challenged tumors.
Unraveling mechanisms of drug resistance: APOBEC3A as a genomic and post-transcriptional driver of treatment resistance in pancreatic cancer
The ADRIP study aims to investigate the role of APOBEC3A in driving drug resistance and intra-tumoral heterogeneity in pancreatic cancer, with potential therapeutic implications.